Everything below concerns Melanotan II. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-18. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
=== 2023 Prachinburi, Thailand === A caesium-137 capsule went missing from a steam power plant in Prachinburi province, Thailand on 23 February 2023, triggering a search by officials from Thailand's Office of Atoms for Peace (OAP) and the Prachinburi provincial administration. However, the Thai public was not notified until 14 March. On 20 March, the Secretary-General of the OAP and the governor of Prachinburi held a press conference stating that they had found caesium-137 contaminated furnace dust at a steel melting plant in Kabin Buri district.
== Effect of molecular weight == At constant pressure and temperature, the root-mean-square speed and therefore the effusion rate are inversely proportional to the square root of the molecular weight. Gases with a lower molecular weight effuse more rapidly than gases with a higher molecular weight, so that the number of lighter molecules passing through the hole per unit time is greater.
A new Constitution, introduced in 1984, re-enfranchised the Coloured population (women as well as men) and enfranchised the Indian population. It retained the existing House of Assembly for whites and established a House of Representatives to represent the Coloureds, and a House of Delegates for the Indians, making Parliament a tricameral legislature. Blacks continued to be excluded.
Sources: en.wikipedia.org
Beefy meaty peptide, also known as delicious peptide and abbreviated as BMP, is an 8-amino acid long peptide that has been identified as giving a beefy flavour to foods in which it is present. It was isolated from beef soup by Yamasaki and Maekawa in 1978. Ongoing research since its discovery by Yamasaki and Maekawa has provided general support for the presence of its flavor-imparting properties. However, due to its high production cost, the peptide's potential for widespread application in the food industry has yet to be realized, prompting current research efforts to focus on finding a method of mass-production for the peptide.
More opioids are taken than intended The individual is unable to decrease the number of opioids used Large amounts of time are spent trying to obtain opioids, use opioids, or recover from taking them The individual has cravings for opioids Difficulty fulfilling professional duties at work or school Continued use of opioids leading to social and interpersonal consequences Decreased social or recreational activities Using opioids despite being in physically dangerous settings Continued use despite opioids worsening physical or psychological health (i.e. depression, constipation) Tolerance Withdrawal The severity can be classified as mild, moderate, or severe based on the number of criteria present. The tolerance and withdrawal criteria are not considered to be met for individuals taking opioids solely under appropriate medical supervision. Addiction and dependence are components of a substance use disorder; addiction is the more severe form.
== History == Efficacy was evaluated in CADENZA (NCT03386513), a multi-center, open-label, single-arm clinical trial that included adult participants with treatment-naïve blastic plasmacytoid dendritic cell neoplasm (N=33) or relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (N=51), without evidence of active central nervous system disease. Efficacy was based on the rate of complete remission or clinical complete remission. The trial included 116 adult participants with CD123-positive blood or bone marrow cancers, of whom 84 participants had blastic plasmacytoid dendritic cell neoplasm. There were 33 participants who had blastic plasmacytoid dendritic cell neoplasm that was never treated before, and 51 participants had blastic plasmacytoid dendritic cell neoplasm that either came back after previous treatment or did not get better with other treatment(s). The trial occurred at 18 locations in four countries: the United States, Italy, Spain, and France. The study included 73 participants in the United States. The benefits and side effects of pivekimab sunirine were evaluated in one open-label trial in adult participants with CD123-positive blood or bone marrow cancers. The efficacy of pivekimab sunirine was evaluated in 84 participants with blastic plasmacytoid dendritic cell neoplasm who received pivekimab sunirine intravenously (through a vein) once every three weeks until the disease worsened or participants experienced unacceptable side effects.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.